Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) and biopharmaceutical company Zai Lab Limited (Nasdaq:ZLAB) (HKEX:9688) revealed on Tuesday that they have received Chinese regulatory approval for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) 1,000mg (5.6ml)/vial for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
The approval is based on positive results from the Phase 3 ADAPT-SC study, which demonstrated similar efficacy and safety compared to the intravenous formulation.
Efgartigimod SC is also being evaluated for chronic inflammatory demyelinating polyneuropathy (CIDP) in China and has been approved for CIDP in the United States.
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
SFA Therapeutics names new chief operating officer
argenx and Zai Lab win China approval for efgartigimod SC
Scinai Immunotherapeutics reports positive results in psoriasis study
Spine BioPharma, signs agreement with Ensol BioSciences
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
Delta-Fly Pharma initiates Phase III trial for lung cancer drug DFP-14323
Q32 Bio added to Russell 3000 Index
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)